Baseline demographic and clinical findings in patients with and without apathy
| All patients | Apathy | No apathy | p Value | |
| (n = 79) | (n = 11) | (n = 68) | ||
| Female, n (%) | 44 (55.7) | 7 (63.6) | 37 (54.4) | 0.746 |
| Age in years (SD) | 72.0 (8.3) | 73.4 (8.4) | 71.8 (8.3) | 0.533 |
| Education in years (SD) | 9.3 (3.3) | 9.0 (2.7) | 9.3 (3.4) | 0.733 |
| Disease duration in years (SD) | 13.0 (4.7) | 14.2 (4.4) | 12.8 (4.8) | 0.297 |
| Total UPDRS motor score (SD) | 28.5 (17.6) | 23.8 (10.2) | 29.3 (18.5) | 0.650 |
| UPDRS motor subscore A (SD) | 18.4 (12.3) | 14.5 (6.9) | 19.0 (12.9) | 0.436 |
| UPDRS motor subscore B (SD) | 7.2 (4.5) | 7.5 (3.7) | 7.2 (4.7) | 0.594 |
| Hoehn and Yahr stage | ||||
| Mean (SD) | 3.0 (0.9) | 3.2 (0.6) | 3.0 (1.0) | 0.306 |
| Range | 1.0–5.0 | 2.5–4.0 | 1.0–5.0 | |
| Montgomery and Aasberg Depression Rating Scale score (SD) | 5.4 (6.7) | 13.3 (7.3) | 4.2 (5.6) | <0.001 |
| Mini-Mental State Examination score (SD) | 25.5 (6.4) | 21.1 (6.7) | 26.2 (6.1) | 0.011 |
| Neuropsychiatric Inventory apathy score (SD) | 1.2 (2.9) | 7.9 (2.6) | 0.1 (0.6) | <0.001 |
| Depression, n (%) | 16 (20.3) | 6 (54.5) | 10 (14.7) | 0.007 |
| Dementia, n (%) | 23 (29.1) | 7 (63.6) | 16 (23.5) | 0.012 |
| Levodopa equivalent dose, mg daily (SD) | 658 (387) | 630 (415) | 663 (386) | 0.456 |
| Antidepressants, n (%) | 14 (17.7) | 3 (27.3) | 11 (16.2) | 0.370 |
| Anxiolytics, n (%) | 7 (8.9) | 1 (9.1) | 6 (8.8) | 0.999 |
| Antipsychotics, n (%) | 9 (11.4) | 3 (27.3) | 6 (8.8) | 0.084 |
Data are expressed as mean (SD) or number (percentage of assessed patients); all available data included. Comparisons between patients with and without apathy: χ2 tests or Fisher exact tests when appropriate for categorical variables, Mann–Whitney tests for continuous variables. All p values are two-tailed.
UPDRS, Unified Parkinson Disease Rating Scale.